Edrophonium-hyoscine butylbromide mixture for reversal of neuromuscular blockade: heart rate changes in infants and children.
The effectiveness of hyoscine butylbromide in the prevention of edrophonium-induced bradycardia was assessed in 50 infants and children. A mixture of edrophonium (1.0 mg/kg) and either atropine (0.01 mg/kg) or hyoscine butylbromide (0.4 mg/kg) was administered to reverse the effects of tubocurarine. An initial bradycardia followed the injection of the edrophonium-atropine mixture. In contrast there was no initial decrease in heart rate after the administration of the edrophonium-hyoscine butylbromide mixture. Hyoscine butylbromide can be used with advantage as a substitute for atropine in edrophonium reversal in infants and children.
Yamashita
M
M
Ibaraki Children's Hospital, Mito, Japan.
Tajima
K
K
D001285:Atropine / Q000494:pharmacology; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D002648:Child; D004491:Edrophonium / Q000494:pharmacology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008297:Male; D012602:Scopolamine Derivatives / Q000494:pharmacology*; D013997:Time Factors; D014403:Tubocurarine / Q000037:antagonists & inhibitors*
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide; D004491:Edrophonium; D001285:Atropine; D014403:Tubocurarine